Help us: Donate
Follow us on:

Tag: BioTime

August 14, 2018
Yet another important investment in the field of regenerative medicine against aging demonstrates the increasing interest of investors in this industry; on August 2, BioTime, Inc. announced that Juvenescence Limited will buy 14.4 million of its subsidiary AgeX Therapeutics' shares for a total of $43.2 million—50% to be paid in cash and 50% with a...